Home » Finance Biotechnology » $42 Million Raised by Marc Beer for Women’s Health

Categories

$42 Million Raised by Marc Beer for Women’s Health

With over 25 years of experience in biotechnology, pharmaceuticals, and diagnostics Marc Beer has now used his expertise and determination to raise approximately $42 million dollars for women’s health. As seen in an article posted by the Boston Business Journal in August of 2018, Beer and his associates are specifically fighting against pelvic floor disorders by pushing towards creating several new products that will be of great use against pelvic floor disorders which affects over 250 million woman from all over the world.

 

Beer was able to allocate approximately $32 million dollars using Series B financing, a method which secures funding through private equity investors as well as venture capitalists. Beer raised the additional $10 million through venture lending which funds working capital and other expenses.

 

Beer has been committed to fighting rare diseases and disorders on a global basis during his time with ViaCell where Beer held the title of CEO. Furthermore, Beer the Miami University alumni not only has experience in developing innovative products for pelvic heath and rare diseases but he has a vast expertise in global marketing as well.

 

Beer is a cofounder and CEO of Renovia, a leading company in the pelvic health industry. During his time working with pelvic health Beer has developed a track record of producing and promoting several innovative interventions in effort to relieve millions of women around the world from pelvic floor disorders.

 

One such product created by Renovia, and it’s first product in pelvic floor health is Leva. Leva is an interactive training device used to help women improve pelvic strength as well as pelvic floor muscle stimulation. Leva assists women whom may struggle with stress related incontinence as well as incontinence due to pelvic floor muscle weakness. This innovative device created by Renovia is a step above other interventions as it does not cary any related side effects.

 

Leva is not the only product which Beer and Renovia are currently working on. Renovia along with The Longwood Fund, an investment firm whose purpose is focused on healthcare are working together towards creating and testing several other therapeutic and diagnostic products.

 

Beer feels passionate about Renovia’s junction with the Longwood Fund announcing that this alliance will support the development of innovative pelvic floor treatments and interventions, along with creating greater awareness of pelvic floor disorders. Beer feels that ultimately this will create further understanding and knowledge of pelvic floor disorders which will not only support millions of women worldwide but will lead to lower healthcare costs as well. Learn more: https://www.bizjournals.com/boston/news/2018/08/21/ex-aegerion-chief-beer-raises-42m-for-womens.html